Skip to main content

ORIGINAL RESEARCH article

Front. Nutr.
Sec. Clinical Nutrition
Volume 12 - 2025 | doi: 10.3389/fnut.2025.1434484

A Multicenter Mixed-Design Study Testing the Effects of Intermittent Fasting on Patients with Immune Thrombocytopenia Receiving Thrombopoietin Receptor Agonists

Provisionally accepted
Mohamed A Yassin Mohamed A Yassin 1,2*Mona Al rasheed Mona Al rasheed 3Taghreed Al Eisa Taghreed Al Eisa 4Noora Alhashmi Noora Alhashmi 5Faisal Alsayegh Faisal Alsayegh 6Tareq Abouzeid Tareq Abouzeid 7Mohamed Abdelfattah Mohamed Abdelfattah 8Maryam Alfili Maryam Alfili 9Neveen Shalaby Neveen Shalaby 10Abdullah Alotaibi Abdullah Alotaibi 11Noura Aljuwaisri Noura Aljuwaisri 12Anwar Almsabahi Anwar Almsabahi 13Rii Adel Rii Adel 14Hind Abd alaziz Hind Abd alaziz 15awni alshurafa awni alshurafa 1omar ismail omar ismail 1Rola Ghasoub Rola Ghasoub 16*
  • 1 Department of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Doha, Qatar
  • 2 College of Medicine, Qatar University, Doha, Qatar
  • 3 Adan Hospital, Kuwait City, Kuwait
  • 4 Ministry of Health, Jahra Hospital, Kuwait., kuwait, Kuwait
  • 5 5. Department of Internal Medicine, Clinical Hematology Unit, Mubarak alkabeer Hospital - MOH, Kuwait, kuwait, Kuwait
  • 6 Faculty of Medicine, Kuwait University, Kuwait City, Kuwait
  • 7 Department of Internal Medicine, Mouwasat Hospital, Dammam, Saudi Arabia
  • 8 Accsight (Saudi Arabia), Jeddah, Saudi Arabia
  • 9 Hematology Unit, Ahmadi Hospital, Kuwait, kuwait, Kuwait
  • 10 Department of Medicine, Al-Adan Hospital, Kuwait, Kuwait
  • 11 Department of Hematology, Kuwait Hospital, Sabah Al Salem, Kuwait
  • 12 Department of Hematology, Amiri Hospital, Kuwait, kuwait, Kuwait
  • 13 14. Department of Internal Medicine, Clinical Hematology Unit, Mubarak alkabeer Hospital - MOH, Kuwait., kuwait, Kuwait
  • 14 Department of Hematology unit, Amiri Hospital, Kuwait., kuwait, Kuwait
  • 15 Department of Hematology unit, Jahra Hospital, Kuwait, kuwait, Kuwait
  • 16 Pharmacy Department.National Center for Cancer Care and Research, Hamad Medical Corporation., Doha, Qatar

The final, formatted version of the article will be published soon.

    In recent years, significant advances have been made in the treatment of immune thrombocytopenia (ITP). This includes the development of novel therapies and the refinement of clinical practice guidelines.The American Society of Hematology (ASH) and International Consensus guidelines recommend the use of thrombopoietin receptor agonists (TPO-RAs) as the preferred second-line therapy for patients with ITP. TPO-RAs have been shown to improve clinical outcomes with minimal side effects. However, it is important to consider factors that may affect drug metabolism and responses, including dietary considerations, route of administration, and cost. In Muslim countries, where religious observance includes 16/8 intermittent fasting, the timing of medication administration may be affected. This 2 multicenter study is the first to evaluate the effect of Ramadan fasting, a type of intermittent fasting, in patients receiving different TPO-RAs.

    Keywords: immune thrombocytopenia, Thrombopoietin receptor agonist, Avatrombopag, eltrombopag, romiplostim, Fasting, ramadan

    Received: 23 Jul 2024; Accepted: 06 Feb 2025.

    Copyright: © 2025 Yassin, Al rasheed, Al Eisa, Alhashmi, Alsayegh, Abouzeid, Abdelfattah, Alfili, Shalaby, Alotaibi, Aljuwaisri, Almsabahi, Adel, Abd alaziz, alshurafa, ismail and Ghasoub. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Mohamed A Yassin, Department of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Doha, Qatar
    Rola Ghasoub, Pharmacy Department.National Center for Cancer Care and Research, Hamad Medical Corporation., Doha, Qatar

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.